Skip to content

US · NEUP · BIOTECHNOLOGY

Neuphoria Therapeutics Inc. (NEUP) intrinsic value and stock valuation

$2.35as of 2026-11-21 · Mkt cap 21.35M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Neuphoria Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values NEUP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NEUP’s statements →

Neuphoria Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Burlington, MA 01803 neuphoriatx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$15.7M+249.5% 5y CAGRd
20112025
Net income
-$-370K
20112025
Free cash flow
$77.2M
20112025
Total equity
$28.9M+27.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$15.7M$0.00$0.00$380K$930K
Operating income-$-1.13M-$-26.79M-$-33.09M-$-31.02M-$-8.96M
Net income-$-370K-$-15.49M-$-32.18M-$-22.94M-$-6.53M
EPSd-$-228.4K-$-103.4K-$-262.93K-$-203.4K-$-100.46K
Operating cash flow$77.2M-$-14.68M-$-9.85M-$-21.75M-$-5.66M
Capital expenditure$0.00$0.00$0.00-$0.00-$0.00
Free cash flow$77.2M-$-14.68M-$-9.85M-$-21.75M-$-5.67M
Total assets$43.4M$27.7M$19.4M$65.3M$40.8M
Total debt$230K$270K$580K$690K$650K
Net debt-$-21.37M-$-12.34M-$-7.8M-$-32.87M-$-20.76M
Total equity$28.9M$17.5M$14.7M$56.9M$35.8M
Cash and short-term investments$21.6M$12.6M$8.06M$33.6M$21.4M
Income statement
20252024202320222021
Revenue$15.7M$0.00$0.00$380K$930K
Cost of revenue$660K$660K$670K$16M$1.69M
Gross profit$15M-$-660K-$-670K-$-9.98M-$-1.27M
Research and development expenses$9.01M$14.1M$19.7M$23.3M$4.33M
Selling, general and administrative expenses$7.77M$8.47M$13.4M$7.69M$4.24M
Other expenses-$-660K-$-4.68M$0.00-$-7.2M$2.68M
Operating expenses$16.1M$17.9M$33.1M$23.7M$11.3M
Cost and expenses$16.8M$17.9M$33.1M$39.8M$12.9M
Interest income$170K$220K$490K$10K$0.00
Interest expense$0.00$0.00$30K$30K$1.08M
Depreciation and amortization$1.01M$990K$1M$1.61M$1.28M
Ebitda-$-120K-$-25.65M-$-31.45M-$-30.25M-$-4.51M
Operating income-$-1.13M-$-26.79M-$-33.09M-$-31.02M-$-8.96M
Total other income/expenses, net$290K$2.31M$700K-$-890K$2.28M
Income before tax-$-840K-$-15.58M-$-32.39M-$-31.9M-$-6.68M
Income tax expense-$-470K$90K-$-210K-$-280K-$-140K
Net income-$-370K-$-15.49M-$-32.18M-$-22.94M-$-6.53M
Weighted average shares outstanding$1.62M$149.8M$122.4M$112.8M$65M
Weighted average diluted shares outstanding$1.62M$149.8M$122.4M$112.8M$65M
Balance sheet
20252024202320222021
Cash and short-term investments$21.6M$12.6M$8.06M$33.6M$21.4M
Net receivables$10K$130K$280K$6.78M$190K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$22.9M$13.2M$8.87M$41.8M$23.2M
Property, plant and equipment, net$160K$220K$220K$670K$650K
Goodwill and intangible assets$20.4M$14.2M$9.87M$22.7M$16.8M
Long-term investments$0.00$80K$50K$0.00$120K
Total non-current assets$20.6M$14.5M$10.5M$23.5M$17.5M
Total assets$43.4M$27.7M$19.4M$65.3M$40.8M
Accounts payable$1.75M$2.24M$960K$1.56M$770K
Short-term debt$230K$160K$270K$160K$130K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$6.41M$3.83M$4.12M$3.36M$1.77M
Long-term debt$0.00$120K$360K$530K$520K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$8.15M$6.33M$2.92M$5.04M$3.23M
Capital lease obligations$180K$240K$530K$690K$650K
Total liabilities$14.6M$10.2M$4.74M$8.4M$5.01M
Common stock$0.00$0.00$0.00$217.7M$142.9M
Retained earnings-$-270.98M-$-177.98M-$-108.16M-$-173.29M-$-115.74M
Accumulated other comprehensive income (loss)-$-4.32M-$-3.01M$3.2M$12.5M$8.6M
Total equity$28.9M$17.5M$14.7M$56.9M$35.8M
Total investments$0.00$80K$50K$0.00$120K
Total debt$230K$270K$580K$690K$650K
Net debt-$-21.37M-$-12.34M-$-7.8M-$-32.87M-$-20.76M
Cash flow statement
20252024202320222021
Net income-$-369.63M-$-15.49M-$-14.38M-$-21.76M-$-6.53M
Depreciation and amortization$662.9M$660K$450K$1.11M$1.28M
Stock-based compensation$163.8M$810K$0.00$2.83M$980K
Change in working capital-$-500K$1.46M$3.08M-$-5.6M$1.23M
Accounts receivable$110K$300K$2.78M-$-5.83M$1.52M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-920K$800K$250K$0.00$0.00
Net cash provided by operating activities$77.2M-$-14.68M-$-9.85M-$-21.75M-$-5.66M
Investments in property, plant and equipment$0.00$0.00$0.00-$0.00-$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$620K-$-60K
Common stock issued$1.53M$10.1M$2.6M$32.9M$32.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.53B$15.1M$5.81M$27M$23.7M
Net change in cash$1.6B$500K-$-15.02M$5.06M$18M
Cash at end of period$14.3B$12.7M$8.06M$33.6M$21.4M
Operating cash flow$77.2M-$-14.68M-$-9.85M-$-21.75M-$-5.66M
Capital expenditure$0.00$0.00$0.00-$0.00-$0.00
Free cash flow$77.2M-$-14.68M-$-9.85M-$-21.75M-$-5.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Neuphoria Therapeutics Inc.

        Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

        CEO
        Spyridon Papapetropoulos
        Employees
        8
        Beta
        0.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Neuphoria Therapeutics Inc. (NEUP)?

        InvestorsCraft does not currently publish an intrinsic value for NEUP. How the IC value is calculated.

        Is NEUP undervalued?

        InvestorsCraft does not publish an undervaluation signal for NEUP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.